These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 32249670)

  • 1. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
    Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
    MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure, heterogeneity and developability assessment of therapeutic antibodies.
    Xu Y; Wang D; Mason B; Rossomando T; Li N; Liu D; Cheung JK; Xu W; Raghava S; Katiyar A; Nowak C; Xiang T; Dong DD; Sun J; Beck A; Liu H
    MAbs; 2019; 11(2):239-264. PubMed ID: 30543482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
    Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
    MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
    Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
    MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties.
    Svilenov HL; Arosio P; Menzen T; Tessier P; Sormanni P
    MAbs; 2023; 15(1):2164459. PubMed ID: 36629855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blueprint for antibody biologics developability.
    Mieczkowski C; Zhang X; Lee D; Nguyen K; Lv W; Wang Y; Zhang Y; Way J; Gries JM
    MAbs; 2023; 15(1):2185924. PubMed ID: 36880643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Therapeutic Antibody Profiler for Computational Developability Assessment.
    Raybould MIJ; Deane CM
    Methods Mol Biol; 2022; 2313():115-125. PubMed ID: 34478133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biophysical properties of the clinical-stage antibody landscape.
    Jain T; Sun T; Durand S; Hall A; Houston NR; Nett JH; Sharkey B; Bobrowicz B; Caffry I; Yu Y; Cao Y; Lynaugh H; Brown M; Baruah H; Gray LT; Krauland EM; Xu Y; Vásquez M; Wittrup KD
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):944-949. PubMed ID: 28096333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection.
    Lavoisier A; Schlaeppi JM
    MAbs; 2015; 7(1):77-83. PubMed ID: 25514497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing developability early in the discovery process for novel biologics.
    Fernández-Quintero ML; Ljungars A; Waibl F; Greiff V; Andersen JT; Gjølberg TT; Jenkins TP; Voldborg BG; Grav LM; Kumar S; Georges G; Kettenberger H; Liedl KR; Tessier PM; McCafferty J; Laustsen AH
    MAbs; 2023; 15(1):2171248. PubMed ID: 36823021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics.
    Zhang W; Wang H; Feng N; Li Y; Gu J; Wang Z
    Antib Ther; 2023 Jan; 6(1):13-29. PubMed ID: 36683767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
    Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
    Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.
    Liu Y; Caffry I; Wu J; Geng SB; Jain T; Sun T; Reid F; Cao Y; Estep P; Yu Y; Vásquez M; Tessier PM; Xu Y
    MAbs; 2014; 6(2):483-92. PubMed ID: 24492294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Holistic in silico developability assessment of novel classes of small proteins using publicly available sequence-based predictors.
    Pais DAM; Mayer JA; Felderer K; Batalha MB; Eichner T; Santos ST; Kumar R; Silva SD; Kaufmann H
    J Comput Aided Mol Des; 2024 Aug; 38(1):30. PubMed ID: 39164492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developability assessment during the selection of novel therapeutic antibodies.
    Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H
    J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An accelerated surface-mediated stress assay of antibody instability for developability studies.
    Kopp MRG; Wolf Pérez AM; Zucca MV; Capasso Palmiero U; Friedrichsen B; Lorenzen N; Arosio P
    MAbs; 2020; 12(1):1815995. PubMed ID: 32954930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pragmatic mAb lead molecule engineering from a developability perspective.
    Chi B; De Oliveira G; Gallagher T; Mitchell L; Knightley L; Gonzalez CC; Russell S; Germaschewski V; Pearce C; Sellick CA
    Biotechnol Bioeng; 2021 Oct; 118(10):3733-3743. PubMed ID: 33913507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools.
    Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R
    Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice.
    Kelly RL; Sun T; Jain T; Caffry I; Yu Y; Cao Y; Lynaugh H; Brown M; Vásquez M; Wittrup KD; Xu Y
    MAbs; 2015; 7(4):770-7. PubMed ID: 26047159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boosting antibody developability through rational sequence optimization.
    Seeliger D; Schulz P; Litzenburger T; Spitz J; Hoerer S; Blech M; Enenkel B; Studts JM; Garidel P; Karow AR
    MAbs; 2015; 7(3):505-15. PubMed ID: 25759214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.